Literature DB >> 26769537

Mitigation of myocardial fibrosis by molecular cardiac surgery-mediated gene overexpression.

Michael G Katz1, Elizabeth Brandon-Warner2, Anthony S Fargnoli3, Richard D Williams4, Andrew P Kendle4, Roger J Hajjar5, Laura W Schrum2, Charles R Bridges6.   

Abstract

OBJECTIVE: Heart failure is accompanied by up-regulation of transforming growth factor beta signaling, accumulation of collagen and dysregulation of sarcoplasmic reticulum calcium adenosine triphosphatase cardiac isoform 2a (SERCA2a). We examined the fibrotic response in small and large myocardial infarct, and the effect of overexpression of the SERCA2a gene.
METHODS: Ischemic cardiomyopathy was induced via creation of large or small infarct in 26 sheep. Animals were divided into 4 groups: small infarct; large infarct with heart failure; gene-treated (large infarct with heart failure followed by adeno-associated viral vector, serotype 1.SERCA2a gene construct transfer by molecular cardiac surgery with recirculating delivery); and control.
RESULTS: Heart failure was significantly less pronounced in the gene-treated and small-infarct groups than in the large-infarct group. Expression of transforming growth factor beta signaling components was significantly higher in the large-infarct group, compared with the small-infarct and gene-treated groups. Both the angiotensin II type 1 receptor and angiotensin II were significantly elevated in the small- and large-infarct groups, whereas gene treatment diminished this effect. Active fibrosis with de novo collagen synthesis was evident in the large-infarct group; the small-infarct and gene-treated groups showed less fibrosis, with a lower ratio of de novo to mature collagen.
CONCLUSIONS: The data presented provide evidence that progression of fibrosis is mediated through increased transforming growth factor beta and angiotensin II signaling, which is mitigated by increased SERCA2a gene expression.
Copyright © 2016 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TGFbeta; fibrosis; gene therapy; myocardial infarction

Mesh:

Substances:

Year:  2015        PMID: 26769537      PMCID: PMC4805528          DOI: 10.1016/j.jtcvs.2015.11.031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  34 in total

Review 1.  Inhibitors of the calcineurin/NFAT pathway.

Authors:  Sara Martínez-Martínez; Juan Miguel Redondo
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

2.  A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.

Authors:  J D Molkentin; J R Lu; C L Antos; B Markham; J Richardson; J Robbins; S R Grant; E N Olson
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

Review 3.  Is angiotensin II a proliferative factor of cardiac fibroblasts?

Authors:  Fatiha Bouzegrhane; Gaétan Thibault
Journal:  Cardiovasc Res       Date:  2002-02-01       Impact factor: 10.787

4.  Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis.

Authors:  Y Akagi; Y Isaka; M Arai; T Kaneko; M Takenaka; T Moriyama; Y Kaneda; A Ando; Y Orita; T Kamada; N Ueda; E Imai
Journal:  Kidney Int       Date:  1996-07       Impact factor: 10.612

Review 5.  Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.

Authors:  Benjamin J Wilkins; Jeffery D Molkentin
Journal:  Biochem Biophys Res Commun       Date:  2004-10-01       Impact factor: 3.575

Review 6.  Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.

Authors:  Jeffery D Molkentin
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

Review 7.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

8.  Decreased concentration of myofibrils and myofiber hypertrophy are structural determinants of impaired left ventricular function in patients with chronic heart diseases: a multiple logistic regression analysis.

Authors:  G Zimmer; R Zimmermann; O M Hess; J Schneider; W Kübler; H P Krayenbuehl; S Hagl; G Mall
Journal:  J Am Coll Cardiol       Date:  1992-11-01       Impact factor: 24.094

9.  Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.

Authors:  Fumitaka Kuwahara; Hisashi Kai; Keisuke Tokuda; Mamiko Kai; Akira Takeshita; Kensuke Egashira; Tsutomu Imaizumi
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

10.  In situ localization of transforming growth factor beta 1 in porcine heart: enhanced expression after chronic coronary artery constriction.

Authors:  M Wünsch; H S Sharma; T Markert; S Bernotat-Danielowski; R J Schott; P Kremer; N Bleese; W Schaper
Journal:  J Mol Cell Cardiol       Date:  1991-09       Impact factor: 5.000

View more
  10 in total

1.  Sex Differences in Metabolic Cardiomyopathy.

Authors:  Elizabeth Murphy; Georgios Amanakis; Natasha Fillmore; Randi J Parks; Junhui Sun
Journal:  Cardiovasc Res       Date:  2017-02-01       Impact factor: 10.787

2.  Technique of Complete Heart Isolation with Continuous Cardiac Perfusion During Cardiopulmonary Bypass: New Opportunities for Gene Therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles Yarnall; Angel Perez; Alice Isidro; Roger J Hajjar; Charles R Bridges
Journal:  J Extra Corpor Technol       Date:  2018-09

3.  Cardiac gene therapy with adeno-associated virus-based vectors.

Authors:  Kyle Chamberlain; Jalish M Riyad; Thomas Weber
Journal:  Curr Opin Cardiol       Date:  2017-05       Impact factor: 2.161

Review 4.  Introducing Genes to the Heart: All About Delivery.

Authors:  Roger J Hajjar; Kiyotake Ishikawa
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

Review 5.  Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure.

Authors:  Michael G Katz; Anthony S Fargnoli; Thomas Weber; Roger J Hajjar; Charles R Bridges
Journal:  Hum Gene Ther Clin Dev       Date:  2017-07-19       Impact factor: 5.032

Review 6.  Human Cardiac Gene Therapy.

Authors:  Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367

7.  Effects of genetic transfection on calcium cycling pathways mediated by double-stranded adeno-associated virus in postinfarction remodeling.

Authors:  Michael G Katz; Sarah M Gubara; Yoav Hadas; Thomas Weber; Arvind Kumar; Efrat Eliyahu; Charles R Bridges; Anthony S Fargnoli
Journal:  J Thorac Cardiovasc Surg       Date:  2019-09-30       Impact factor: 5.209

8.  Analysis of recombinant adeno-associated viral vector shedding in sheep following intracoronary delivery.

Authors:  Melad Farraha; Michael A Barry; Juntang Lu; Jim Pouliopoulos; Thi Y L Le; Sindhu Igoor; Renuka Rao; Cindy Kok; James Chong; Eddy Kizana
Journal:  Gene Ther       Date:  2019-08-29       Impact factor: 5.250

9.  Impact of oxidative posttranslational modifications of SERCA2 on heart failure exacerbation in young patients with non-ischemic cardiomyopathy: A pilot study.

Authors:  Takumi Toya; Kei Ito; Kazuki Kagami; Ayumu Osaki; Atsushi Sato; Toyokazu Kimura; Shunpei Horii; Risako Yasuda; Takayuki Namba; Yasuo Ido; Yuji Nagatomo; Katsumi Hayashi; Nobuyuki Masaki; Hirotaka Yada; Takeshi Adachi
Journal:  Int J Cardiol Heart Vasc       Date:  2019-11-14

10.  Primary Effect of SERCA 2a Gene Transfer on Conduction Reserve in Chronic Myocardial Infarction.

Authors:  Lukas J Motloch; Marine Cacheux; Kiyotake Ishikawa; Chaoqin Xie; Jun Hu; Jaume Aguero; Kenneth M Fish; Roger J Hajjar; Fadi G Akar
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.